Monroe Capital announced it acted as sole lead arranger and administrative agent on the funding of a $20 million senior credit facility to support the growth of Cytovance Biologics by private equity sponsor, Great Point Partners.

Oklahoma City, OK-based Cytovance is a contract manufacturing organization of mammalian and microbial biologics. The company works with biotechnology and pharmaceutical companies in the development and manufacturing of proteins, antibodies, and cell-based therapeutic products. Cytovance supports its customers from clinical development to commercial launch in domestic and international markets.